Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The aim of this study is to analyze if administration of conestat alfa for 72 hours in addition to standard of care (SOC) in patients hospitalized with non-critical SARS-CoV-2 pneumonia (WHO Ordinal Scale Score 3 or 4) reduces the risk of disease progression to Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS).
Description: Disease severity on the 7-point Ordinal World Health Organization (WHO) scale (for the current study, score 0 will be omitted and score 6 and 7 will be combined). The ordinal scale measures illness severity over time. This endpoint has been suggested by WHO for clinical trials in patients with COVID-19.
Measure: Disease severity Time: on day 7Description: Time to clinical improvement (time from randomisation to an improvement of two points on the seven-category WHO ordinal scale or live discharge from hospital, whichever came first)
Measure: Time to clinical improvement Time: within 14 days after enrolmentDescription: Proportion of participants alive and not having required invasive or non-invasive ventilation
Measure: Proportion of participants alive and not having required invasive or non-invasive ventilation Time: at 14 days after enrolmentDescription: Proportion of subjects with an ALI (defined by PaO2/FiO2 ratio of <300mmHg)
Measure: Proportion of subjects with an ALI (defined by PaO2/FiO2 ratio of <300mmHg) Time: within 14 days after enrolmentDescription: Changes in the ordinal WHO scale
Measure: Changes in the ordinal WHO scale Time: from baseline over 14 daysDescription: Length of hospital stay in survivors
Measure: Length of hospital stay in survivors Time: until day 28Description: Proportion of participants progressing to mechanical ventilation
Measure: Proportion of participants progressing to mechanical ventilation Time: on day 7 and day 14Description: Proportion of participants requiring ICU treatment
Measure: Proportion of participants requiring ICU treatment Time: on day 7 and 14Description: Length of ICU stay
Measure: Length of ICU stay Time: until day 28Description: 28 Ventilator-free days
Measure: 28 Ventilator-free days Time: until day 28Description: All-cause mortality
Measure: All-cause mortality Time: time from randomisation to death within four weeksDescription: Changes in biomarker level CRP
Measure: Changes in biomarker level CRP (mg/l) Time: until day 14Description: Changes in biomarker level LDH
Measure: Changes in biomarker level LDH (U/l) Time: until day 14Description: Changes in biomarker level D-Dimer
Measure: Changes in biomarker level D- Dimer (yg/ml) Time: until day 14Description: Changes in biomarker level Ferritin
Measure: Changes in biomarker level Ferritin (ng/ml) Time: until day 14Description: Changes in biomarker level IL-6
Measure: Changes in biomarker level Interleukin 6 (IL- 6) (pg/ml) Time: until day 14Description: Changes in lymphocyte count
Measure: Changes in lymphocyte count (cells per microliter of blood) Time: until day 14Description: Time to virological clearance of SARS-CoV-2 by PCR from upper or lower respiratory tract samples
Measure: Time to virological clearance of SARS-CoV-2 by PCR from upper or lower respiratory tract samples Time: time from enrolment to first of 2 negative assays at least 12 hours apartDescription: Proportion of patients receiving additional anti-inflammatory treatment such as tocilizumab or immunoglobulins
Measure: Proportion of patients receiving additional anti-inflammatory treatment such as tocilizumab or immunoglobulins Time: within 14 daysDescription: Time to defervescence (temperature <38.0°C)
Measure: Time to defervescence (temperature <38.0°C) Time: sustained for at least 48 hoursDescription: Time to clinical improvement (defervescence, normalization of oxygen saturation (>93%) and respiratory rate)
Measure: Time to clinical improvement (defervescence, normalization of oxygen saturation (>93%) and respiratory rate) until day 28 Time: until day 28Description: Duration of supplemental oxygen
Measure: Duration of supplemental oxygen Time: until day 28Description: Peak serum concentration of conestat alfa will be measured
Measure: Change in pharmacokinetics of conestat alfa Time: at baseline, day 1, day 3, day 7, day 10 (during admission) and day 14 (1/- 2days) or discharge dateDescription: Change in pharmacodynamics of conestat alfa (C1-inhibitor (CI-INH) concentration)
Measure: Change in pharmacodynamics of conestat alfa (C1-inhibitor (CI-INH) concentration) Time: at baseline, day 1, day 3, day 7, day 10 (during admission) and day 14 (1/- 2days) or discharge dateAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports